|  |
| Glaxo Vies for a Second Act in HIV
| A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. | | | J&J Slims Down Elan Offer sans Tysabri
| | Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move. | | | GSK Signs $120M Deal to Market DMab Overseas
| | Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved. | | | GSK Teams with Shenzhen Neptunus for Chinese Vaccines
| | GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people. | | | GSK Signs Deal with Concert Pharma to the Tune of $1 Billion
| | GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body. | | | GSK Grabs Derma Firm for $2.9 Billion
| | Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line. | | | Pfizer and Glaxo Join Forces in HIV Venture
| | The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market. | | | A Season in Financial Hell
| | From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal. | | | Gilead Buys CV Therapeutics (Update 1)
| | The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion. | |  MORE ARTICLES
|
| |
| |
| |
| India: An Emerging Knowledge Superpower
| | "India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making. | | | | MORE ARTICLES
|
| |
| Sidewiki: What's Pharma to Do?
| | Google opened up a whole new era of social media when it released Sidewiki - a tool that allows anyone to comment on any Web site. Now pharma has a new battle to fight. | | | Sanofi Warned for Misleading Tent Card
| | Sure, prescription information for Sanofi-Aventis's Uroxatral appears on the back of the tent card, but how can consumer?s see it if it's mounted to a pharmacy wall? | | | Making Big Waves
| | How a small competitor benefited from the use of interactive marketing. | | | Innovation By Design
| | Executives should embrace design to discover new markets and find new ways to server customers. | | | Pharma-Targeted Brandjacking on the Rise
| | Illegal online pharmacies are on the rise, brandjacking dozens of big name pharmaceuticals and netting almost $11 billion in sales this year alone. With consumers on the hunt for affordable meds, the trend is only going to get worse. | | | An Open Conversation
| | Big Pharma navigates a regulatory minefield to reach social media consumers. It's anything but 'business as usual.' | | | Maximize Your Marketing Spend
| | Close the loop between the pros and the consumers by integrating patient-physician communications into pharma brand planning. | | | The Power of Joe
| | With the emergence of user-generated content, marketers have to keep up on the buzz around their brands and categories on the Web. | | | Relationship Building
| | The prescription for better pharma marketing: Gain understanding of your physician-customers by leveraging key analytical insights. | | | MORE ARTICLES
|
| |
| |
| Pharma Trials Heading South
| | Diversity of ethnic groups and prevalence of Spanish language make Latin America an attractive destination for clinical trials. | | | No Such Thing as Free Drugs?
| | New medicines program may be a beacon of light for the newly jobless, but some wonder what issues might arise from such a ?good gesture.? | | | Wrangling Over Research Results
| | Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion. | | | A Review of Tafas v. Doll | | Appeals court paves the way for Patent and Trademark Office to adopt restrictive patent rules. | | | New Study Reveals Distribution Trends in Drug Sampling
| | Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees. | | | Data Mining Companies Score Legal Win in Maine
| | IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms. | | | BioMS Medical Signs $500 Million Agreement with Lilly
| | Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. | | | Preemption Gets Boost from Bush
| | State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer? | | | BMS Cuts Bloated Manufacturing Arm to Bolster R&D
| | Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing. | | | MORE ARTICLES
|
| |
| GSK Chooses MediaCom for a Billion-Dollar Planner Contract
| | GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion. | | | Vertex Pharmaceuticals Brings Transparency Online
| | Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media. | | | Arkansas Attorney General Takes J&J to Task
| | The State of Arkansas filed suit against Risperdal manufacturer Johnson & Johnson, claiming promotion of the drug for nonmedical uses has led to increased prescriptions being written and bigger payouts by Medicaid. | | | In Defense of Peer Review: Waxman Opponents Argue for Distribution of Off-Label Info
| | Peer-review advocates speak out against Congressman Waxman?s stance on a new policy that would allow pharma to distribute unbiased journal articles to doctors without prior approval. | | | Doc-Driven Search Site Lists Top Search Terms
| | A physician-oriented search engine reveals its most-searched terms. Among the winners: breast and lung cancer, cortisol, and HbA1c/glycated hemoglobin. Nowhere to be seen: pharmaceutical products. | | | Discovery Health Documentary Spotlights Diabetes and Offers a CME Credit
| | A new pharma-sponsored documentary chronicles one doctor?s adventure around the world as she searches for stories about living with diabetes. The program, sponsored by Novo Nordisk, enlightens viewers and offers physicians a chance to earn one AMA-approved CME credit. | | | GSK Told to Update Avandia Warnings
| | Faced with contradictory data about the safety of the diabetes treatment, FDA asks for a black-box warning and additional trials. But how much damage will the black box do? | | | Lilly's New Blood Thinner No Blockbuster
| | Safety Risks, Generic Threat Scale Down Big Hopes | | | Stormy Forecast for Pharma in 2008
| | Bright Spots Are Emerging Markets, Specialty Drugs, Says IMS Health | | | MORE ARTICLES
|
| |
| Innovation Over Imitation
| | As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics. | | | Biomarkers: Promises and Challenges
| | Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development. | | | Finding the Sweet Spot
| | How proper site activation and site enrollment can help you get the most from clinical trials. | | | NHLBI Cans Sildenafil Study After Reports of Severe Pain
| | Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra. | | | The Rx for R&D
| | The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies? | | | Statins Get Boost from New Study
| | Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal. | | | Swallowing the Innovator's Rx
| | Capitalize on the new age in healthcare with "disruptive innovation." | | | ASCO Roundup: Winners, Losers, and Also Rans
| | Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. | | | How Evidence Based Medicine is Impacting Global Clinical and Reimbursement Practices
| | Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world | | | MORE ARTICLES
|
| |
| The Changing Pharmaceutical Sales Landscape
| | Sales forces can achieve compliance and excellence through individual behavioral fine-tuning and company-wide cultural adjustment. | | | Managing the Crisis of Marginalization
| | The key to managing the pharma sales force is to know when the customer wants good customer service, and when the customer needs good self-service. | | | Rx Scripts Spike in Wake of Swine Flu
| | New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing. | | | Higher Learning for Pharma Sales Reps
| | American Society of Hypertension to launch new education program that grants sales reps hypertension accreditation after rigorous training. | | | US Pharma Market To Decline in 2009
| | IMS has revised its 2009, forecast and the outlook isn't pretty for the United States, which looks to drop 1 to 2 percent in the coming year. | | | Goodbye, Willy Loman
| | The days of pharma sales reps going office-to-office with samples and brochures are done. These days, they need to turn their attention to payers, pharmacists, and consumers | | | Make a Match
| | Big Pharma is finally making a commitment to partner-based outsourcing. | | | Drug Sales See Minimal Climb in 2008
| | Farewell to double-digit growth. Between patent expirations and a sagging economy, sales of prescription drugs grew only 1.3 percent last year. | | | The New Sales Force
| | The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with—and how it's working | | | MORE ARTICLES
|
| |
| Innovation Over Imitation
| | As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics. | | | Glaxo Vies for a Second Act in HIV
| | A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. | | | J&J Cuts Staff in Major Restructuring Move
| | Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce. | | | Global Pharma Market Growth to Grow 4 to 6 Percent in 2010
| | Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates. | | | H1N1 Vaccine Hits the Market
| | Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe? | | | The Book on Daniel
| | Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that? | | | Are You Ready For The Revolution?
| | Seven Global Trends shaping the future of the pharmaceutical industry. | | | Pharm Exec Q&A: GSK's Deirdre Connelly
| | Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move—spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more. | | | Lilly Shuffles Staff, Cuts Thousands of Jobs
| | Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011. | | | MORE ARTICLES
|
| |
| Listen to a preview of Drugs, Devices or Data - Which is Most Valuable? Webcast
| | | | Cut the Cord and Take to the Cloud
| | One feature that should be considered when looking for a new software-as-a-service (SaaS) system is multi-tenancy, which is a chief characteristic of a mature cloud computing application. Here?s what to look for. | | | Calculating Risk
| | A risk-based approach to records and information management can be an integral part of the effort to reduce costs stemming from litigation. | | | Bank on IT
| | Tough economic tmes call for a bold approach to evolving information technology solutions. | | | Search for: Meaning
| | Here's how to search for meaning through unstructured data. | | | Ortho-McNeil Talks ADHD On Facebook
| | The Johnson & Johnson subsidiary launched an unbranded support group page on social networking site Facebook giving moms of kids with ADHD a place to learn, but not a place to converse. | | | J&J Goes From Boob Tube to YouTube
| | Johnson & Johnson launched its healthcare video channel on Google?s YouTube, signaling pharma?s further entrenchment into the online community | | | Genzyme Launches Digital Assault on Counterfeiters
| | Rather than wait to see which ePedigree legislation becomes law, biotech firm Genzyme has taken the initiative and implemented an electronic track-and-trace program to clamp down on fake meds. | | | Researchers to Share Ideas in Virtual Park
| | The Hershey Center for Applied Research is bringing social networking to researchers and academics with a new platform that could become a Facebook for the life science community. Does the site, dubbed KnowledgeMesh, have what it takes cut through the Web 2.0 clutter? Pharm Exec takes a closer look. | | | MORE ARTICLES
|
|
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Conducting clinical trials in emerging regions can give you the edge. Five Quintiles experts share their insights into navigating the global regulatory landscape.